![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication May 2, 2005.
Revised July 12, 2005.
Accepted for publication July 12, 2005.
Nonpeptidic delta-opioid agonists produce a number of behaviors, such as antidepressant-like effects, locomotor stimulation, antinociception, and convulsions. To consider this class of compounds as potential therapeutics for humans, the effects of delta-opioid agonists following repeated administration must be evaluated. Therefore, the present study investigated the effects of repeated delta-opioid agonist (SNC80) administration on its antidepressant-like effects in the forced swim test, locomotor activity, and convulsions. Tolerance developed rapidly to the convulsive and locomotor-stimulating effects of SNC80, but not to the antidepressant-like effects. In addition, tolerance was evaluated at the level of the receptor-G protein interaction by measuring [35S]GTP
S binding in brains from rats that were pretreated with SNC80. With various exposure durations to SNC80, some brain regions demonstrated tolerance at different times, suggesting that adaptations in the delta-opioid system may occur during agonist exposure. Overall, the lack of observable tolerance to the antidepressant-like effects of SNC80 indicates that this class of compounds has potential as a novel antidepressant therapy.
Key words:
G protein activation, SNC80, behavior, delta-opioid receptors, rats, tolerance
This article has been cited by other articles:
|
|
 |
|
  E. M. Jutkiewicz, M. G. Baladi, J. E. Folk, K. C. Rice, and J. H. Woods The {delta}-Opioid Receptor Agonist SNC80 [(+)-4-[{alpha}(R)-{alpha}-[(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N,N-diethylbenzamide] Synergistically Enhances the Locomotor-Activating Effects of Some Psychomotor Stimulants, but Not Direct Dopamine Agonists, in Rats J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 714 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Yadav, K. Chaturvedi, and R. D. Howells Inhibition of Agonist-Induced Down-Regulation of the {delta}-Opioid Receptor with a Proteasome Inhibitor Attenuates Opioid Tolerance in Human Embryonic Kidney 293 Cells J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1186 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Jutkiewicz The Antidepressant -like Effects of Delta-Opioid Receptor Agonists Mol. Interv., June 1, 2006; 6(3): 162 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Jutkiewicz, M. G. Baladi, J. E. Folk, K. C. Rice, and J. H. Woods The Convulsive and Electroencephalographic Changes Produced by Nonpeptidic {delta}-Opioid Agonists in Rats: Comparison with Pentylenetetrazol J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1337 - 1348. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
